HFpEF patients often have hypertension, hyperglycemia, and obesity, which increase the risk of morbidity and mortality [39], but these conditions can be positively impacted by SGLT2 inhibitors, potentially benefiting those patients [40]. This evidence concerns the gene SLC5A2 and Obesity.